Materials and Methods

Between 1 June- 31 December 2019, 224 patients with moderate-severe acne vulgaris who administered oral ISO (0.5-1 mg/kg/day) at the Department of Dermatology and Venereology of the Regional Training and Research Hospital were included in this study. Written consent forms were obtained from 203 adult patients and parents of 21 adolescent patients. Patients who used any medication (iron, vitamin supplements, statins, etc.) that could affect hematological parameters and lipid profile in the last 3 months were excluded. All patients were selected from the group of 15-35 years of age to be able to minimize the possibility of atherosclerosis comorbidity as it may affect the inflammatory parameters. Patients with cancer, severe infection, hematological diseases (including iron-deficiency anemia), heart failure, and lung diseases were excluded. Data such as gender, age, CBC, lipid profile, and the serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, and uric acid levels were obtained from the electronic registration database. In the pre-treatment phase and 3 months after treatment, white blood cell (WBC), neutrophil, lymphocyte, monocyte and platelet counts, MPV, PTC, NLR, PLR, monocyte/lymphocyte ratio (MLR), MHR, serum triglyceride (TG), total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels were analyzed.
This single-center cross-sectional retrospective-study was approved by the Ethics Committee of the Regional Training and Research Hospital, Erzurum, Turkey (Decision No: 2020/12-134). This study was conducted per the latest version of the ”Helsinki Declaration” and ”Guidelines for Good Clinical Practice”.